
Pharmacy Community Reacts to Cigna/Express Scripts Deal
Critics point to reduced competition, higher costs.
Industry insiders are buzzing about the impact Cigna’s $67 billion acquisition of Express Scripts will have on healthcare.
B. Douglas Hoey, MBA, CEO of NCPA tells Drug Topics that while the organization is still assessing the implications of the merger, one thing is clear: “Consolidation among healthcare giants leads to fewer choices for patients and plan sponsors.”
Hoey says merging healthcare companies tend to claim their moves will result in cost savings to patients and health plan sponsors, but the available evidence from previous consolidations suggests otherwise. The merger of
Related article:
“We’re seeing the growing balkanization of the healthcare industry-a world in which patients may be forced into a healthcare kingdom: the CVS-Aetna kingdom, the Cigna-Express Scripts kingdom, the UnitedHealth-OptumRx kingdom, et cetera-where the borders aren’t porous, and patients are stuck with what they get,” says Hoey.
He adds that lack of choice could trap some patients in inflexible pharmacy and healthcare networks that dictate the decision-making process for the delivery of care.
“We have expressed significant concerns about the proposed CVS-Aetna [deal] and believe similar concerns apply in this instance,” Hoey says. Continued vertical healthcare consolidation could impede competition and foreclose any meaningful entry into the market, leading to fewer choices and higher healthcare costs.” Hoey says NCPA believes rigorous antitrust scrutiny is critical to protect competition and ensure affordable patient access.
Adam J. Fein, PhD, CEO of
Fein says the strategic logic behind the merger is much more evident for Express Scripts than Cigna. “Perhaps that’s why the stocks reacted so differently [the day the merger was announced]. Express Scripts’ stock closed up 9%, while Cigna’s stock closed down 12%.”
Al Babbington, CEO of PrescribeWellness, a cloud-based healthcare communication company that helps healthcare professionals address medication adherence issues, says transparency on drug pricing is paramount to the reduction of costs, and consumers want to be empowered with knowledge and choice. “These factors will destroy the old PBM models. It's not surprising the largest independent PBM has found a new home."
Babbington adds: "I am concerned that this acquisition, like the
Related article:
Frederick Mayer, RPh, CEO of Pharmacy Planning Services Inc., says that over the past 10 years similar large mergers between insurance carriers, PBMs, and managed care organizations have not resulted in much better healthcare or lower prescription drug costs. “We have seen these mergers resulting in larger prices for prescription drugs, larger premiums for patients and consumers, and no better quality of care being documented,” says Mayer. PPSI promotes consumer public health education and pharmaceutical information.
In a press release, Cigna and Express Scripts asserted that the acquisition will create an expanded portfolio of health services, deliver greater consumer choice, and put health and pharmacy services within reach of everyone that they serve.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.


























































































































































